179 related articles for article (PubMed ID: 22613809)
1. Frequent activation of EGFR in advanced chordomas.
Dewaele B; Maggiani F; Floris G; Ampe M; Vanspauwen V; Wozniak A; Debiec-Rychter M; Sciot R
Clin Sarcoma Res; 2011 Jul; 1(1):4. PubMed ID: 22613809
[TBL] [Abstract][Full Text] [Related]
2. Analysis of receptor tyrosine kinases (RTKs) and downstream pathways in chordomas.
Tamborini E; Virdis E; Negri T; Orsenigo M; Brich S; Conca E; Gronchi A; Stacchiotti S; Manenti G; Casali PG; Pierotti MA; Pilotti S
Neuro Oncol; 2010 Aug; 12(8):776-89. PubMed ID: 20164240
[TBL] [Abstract][Full Text] [Related]
3. Tyrosine kinase receptor expression in chordomas: phosphorylated AKT correlates inversely with outcome.
de Castro CV; Guimaraes G; Aguiar S; Lopes A; Baiocchi G; da Cunha IW; Campos AH; Soares FA; Begnami MD
Hum Pathol; 2013 Sep; 44(9):1747-55. PubMed ID: 23618355
[TBL] [Abstract][Full Text] [Related]
4. The role of epidermal growth factor receptor in chordoma pathogenesis: a potential therapeutic target.
Shalaby A; Presneau N; Ye H; Halai D; Berisha F; Idowu B; Leithner A; Liegl B; Briggs TR; Bacsi K; Kindblom LG; Athanasou N; Amary MF; Hogendoorn PC; Tirabosco R; Flanagan AM
J Pathol; 2011 Feb; 223(3):336-46. PubMed ID: 21171079
[TBL] [Abstract][Full Text] [Related]
5. Coactivated platelet-derived growth factor receptor {alpha} and epidermal growth factor receptor are potential therapeutic targets in intimal sarcoma.
Dewaele B; Floris G; Finalet-Ferreiro J; Fletcher CD; Coindre JM; Guillou L; Hogendoorn PC; Wozniak A; Vanspauwen V; Schöffski P; Marynen P; Vandenberghe P; Sciot R; Debiec-Rychter M
Cancer Res; 2010 Sep; 70(18):7304-14. PubMed ID: 20685895
[TBL] [Abstract][Full Text] [Related]
6. Immunohistochemical analysis of receptor tyrosine kinase signal transduction activity in chordoma.
Fasig JH; Dupont WD; LaFleur BJ; Olson SJ; Cates JM
Neuropathol Appl Neurobiol; 2008 Feb; 34(1):95-104. PubMed ID: 17973908
[TBL] [Abstract][Full Text] [Related]
7. Aberrant hyperactivation of akt and Mammalian target of rapamycin complex 1 signaling in sporadic chordomas.
Han S; Polizzano C; Nielsen GP; Hornicek FJ; Rosenberg AE; Ramesh V
Clin Cancer Res; 2009 Mar; 15(6):1940-6. PubMed ID: 19276265
[TBL] [Abstract][Full Text] [Related]
8. Receptor tyrosine kinase and downstream signalling analysis in diffuse malignant peritoneal mesothelioma.
Perrone F; Jocollè G; Pennati M; Deraco M; Baratti D; Brich S; Orsenigo M; Tarantino E; De Marco C; Bertan C; Cabras A; Bertulli R; Pierotti MA; Zaffaroni N; Pilotti S
Eur J Cancer; 2010 Oct; 46(15):2837-48. PubMed ID: 20692828
[TBL] [Abstract][Full Text] [Related]
9. Methylthioadenosine phosphorylase and activated insulin-like growth factor-1 receptor/insulin receptor: potential therapeutic targets in chordoma.
Sommer J; Itani DM; Homlar KC; Keedy VL; Halpern JL; Holt GE; Schwartz HS; Coffin CM; Kelley MJ; Cates JM
J Pathol; 2010 Apr; 220(5):608-17. PubMed ID: 20140939
[TBL] [Abstract][Full Text] [Related]
10. Potential therapeutic targets for chordoma: PI3K/AKT/TSC1/TSC2/mTOR pathway.
Presneau N; Shalaby A; Idowu B; Gikas P; Cannon SR; Gout I; Diss T; Tirabosco R; Flanagan AM
Br J Cancer; 2009 May; 100(9):1406-14. PubMed ID: 19401700
[TBL] [Abstract][Full Text] [Related]
11. ErbB/HER receptor activation and preclinical efficacy of lapatinib in vestibular schwannoma.
Ammoun S; Cunliffe CH; Allen JC; Chiriboga L; Giancotti FG; Zagzag D; Hanemann CO; Karajannis MA
Neuro Oncol; 2010 Aug; 12(8):834-43. PubMed ID: 20511180
[TBL] [Abstract][Full Text] [Related]
12. Coactivation of receptor tyrosine kinases in malignant mesothelioma as a rationale for combination targeted therapy.
Brevet M; Shimizu S; Bott MJ; Shukla N; Zhou Q; Olshen AB; Rusch V; Ladanyi M
J Thorac Oncol; 2011 May; 6(5):864-74. PubMed ID: 21774103
[TBL] [Abstract][Full Text] [Related]
13. The Role of EGFR, Hepatocyte Growth Factor Receptor (c-Met), c-ErbB2 (HER2-neu) and Clinicopathological Parameters in the Pathogenesis and Prognosis of Chordoma.
Tosuner Z; Bozkurt SU; Kiliç T; Yilmaz B
Turk Patoloji Derg; 2017; 33(2):112-120. PubMed ID: 28272674
[TBL] [Abstract][Full Text] [Related]
14. Gain of chromosome 7 by chromogenic in situ hybridization (CISH) in chordomas is correlated to c-MET expression.
Walter BA; Begnami M; Valera VA; Santi M; Rushing EJ; Quezado M
J Neurooncol; 2011 Jan; 101(2):199-206. PubMed ID: 20617367
[TBL] [Abstract][Full Text] [Related]
15. Molecular targeted therapies in advanced or metastatic chordoma patients: facts and hypotheses.
Lebellec L; Aubert S; Zaïri F; Ryckewaert T; Chauffert B; Penel N
Crit Rev Oncol Hematol; 2015 Jul; 95(1):125-31. PubMed ID: 25682222
[TBL] [Abstract][Full Text] [Related]
16. Prognostic Relevance and In Vitro Targeting of Concomitant PTEN and p16 Deficiency in Chordomas.
Seeling C; Mosca E; Mantel E; Möller P; Barth TFE; Mellert K
Cancers (Basel); 2023 Mar; 15(7):. PubMed ID: 37046638
[TBL] [Abstract][Full Text] [Related]
17. Notochordal Tumors: An Update on Molecular Pathology with Therapeutic Implications.
Yamaguchi T; Imada H; Iida S; Szuhai K
Surg Pathol Clin; 2017 Sep; 10(3):637-656. PubMed ID: 28797506
[TBL] [Abstract][Full Text] [Related]
18. Genome-wide DNA methylation profiling of recurrent and non-recurrent chordomas.
Alholle A; Brini AT; Bauer J; Gharanei S; Niada S; Slater A; Gentle D; Maher ER; Jeys L; Grimer R; Sumathi VP; Latif F
Epigenetics; 2015; 10(3):213-20. PubMed ID: 25621392
[TBL] [Abstract][Full Text] [Related]
19. Chordoma: the entity.
Yakkioui Y; van Overbeeke JJ; Santegoeds R; van Engeland M; Temel Y
Biochim Biophys Acta; 2014 Dec; 1846(2):655-69. PubMed ID: 25193090
[TBL] [Abstract][Full Text] [Related]
20. Novel therapeutic targets in chordoma.
Bydon M; Papadimitriou K; Witham T; Wolinsky JP; Bydon A; Sciubba D; Gokaslan Z
Expert Opin Ther Targets; 2012 Nov; 16(11):1139-43. PubMed ID: 22860993
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
